Wellcome Centre for Anti-Infective Research at the University of Dundee

12-15 May 2019
Dundee, UK

  • Isabela Ribeiro, Head of Dynamic Portfolio Unit – presentation on clinical trials for Chagas disease
  • Nick White, Chair DNDi SAC – presentation on the global situation in infectious diseases & drug discovery for infectious diseases
  • Poster presentations on drug discovery projects for Chagas disease and leishmaniasis

R&D Portfolio Update February 2019: DNDi Leishmaniasis programme

In Africa, results of a Phase III study on HIV/VL in Ethiopia showed high efficacy of a new combination therapy for co-infected patients, a Phase III study began to test new combination treatment for visceral leishmaniasis, and a Phase II study testing new treatments for PKDL started in Sudan. In Asia, the results of an infectivity study in Bangladesh confirmed that PKDL acts as a reservoir for leishmaniasis infection, with implications for elimination efforts across South Asia. In Latin America, the Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.

R&D Portfolio Update February 2019: DNDi Chagas disease programme

A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.